Organ Protection With Sevoflurane Postconditioning

NCT ID: NCT00518908

Last Updated: 2011-07-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

125 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-01-31

Study Completion Date

2010-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Organ protection, volatile anesthetics, postconditioning, hepatic surgery

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study aims at the evaluation of a potential attenuation of ischemic-reperfusion injury in the liver with sevoflurane postconditioning upon reperfusion.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatectomy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sevoflurane

Sevoflurane for pharmacological postconditioning

Group Type EXPERIMENTAL

Sevoflurane

Intervention Type DRUG

3.2 Vol % for postconditioning

Propofol

Anesthesia maintenance with propofol instead of Sevoflurane postconditioning

Group Type EXPERIMENTAL

Sevoflurane

Intervention Type DRUG

3.2 Vol % for postconditioning

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sevoflurane

3.2 Vol % for postconditioning

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* older than 18 years
* patients undergoing liver resection (benign or malignant tumors)

Exclusion Criteria

* non-german speakers
* laparoscopic liver resection
* coagulopathy (platelets \< 50'000/ml, Quick \< 50%)
* liver cirrhosis
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Zurich

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

University Hospital Zurich, Department of Anesthesiology

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

01 Studienregister MasterAdmins

Role: STUDY_DIRECTOR

UniversitaetsSpital Zuerich

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital of Zurich

Zurich, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

StV 34-2007

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Sevoflurane in Cardiac Surgery
NCT00821262 COMPLETED PHASE4